Aarey Drugs & Pharmaceuticals Ltd
Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse
industrial applications[1]
- Market Cap ₹ 162 Cr.
- Current Price ₹ 57.8
- High / Low ₹ 75.8 / 37.0
- Stock P/E 23.4
- Book Value ₹ 48.5
- Dividend Yield 0.00 %
- ROCE 6.09 %
- ROE 3.74 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.19 times its book value
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 2.22% over past five years.
- Tax rate seems low
- Company has a low return on equity of 4.32% over last 3 years.
- Earnings include an other income of Rs.7.03 Cr.
- Company has high debtors of 170 days.
- Promoter holding has decreased over last 3 years: -4.10%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
172 | 200 | 213 | 246 | 396 | 349 | 354 | 298 | 348 | 493 | 419 | 396 | 519 | |
170 | 198 | 212 | 245 | 386 | 342 | 347 | 294 | 344 | 481 | 411 | 391 | 513 | |
Operating Profit | 2 | 1 | 1 | 1 | 10 | 8 | 8 | 3 | 5 | 11 | 8 | 4 | 6 |
OPM % | 1% | 1% | 1% | 0% | 2% | 2% | 2% | 1% | 1% | 2% | 2% | 1% | 1% |
0 | 2 | 3 | 3 | 3 | 3 | 4 | 7 | 7 | 3 | 3 | 7 | 7 | |
Interest | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 2 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 5 |
Profit before tax | 1 | 1 | 1 | 2 | 8 | 8 | 9 | 7 | 8 | 10 | 6 | 5 | 7 |
Tax % | 27% | 22% | 23% | 29% | 31% | 25% | 27% | 20% | 21% | 35% | 37% | 12% | |
1 | 1 | 1 | 1 | 5 | 6 | 7 | 6 | 7 | 7 | 4 | 5 | 7 | |
EPS in Rs | 0.39 | 0.62 | 0.65 | 0.77 | 3.02 | 2.64 | 2.80 | 2.48 | 2.78 | 2.58 | 1.49 | 1.67 | 2.53 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 2% |
3 Years: | 4% |
TTM: | 55% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | -6% |
3 Years: | -10% |
TTM: | 108% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | 26% |
3 Years: | 13% |
1 Year: | 27% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 5% |
3 Years: | 4% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 17 | 17 | 17 | 17 | 18 | 23 | 23 | 23 | 23 | 25 | 25 | 28 | 28 |
Reserves | 17 | 18 | 19 | 20 | 31 | 57 | 63 | 69 | 75 | 88 | 92 | 105 | 108 |
5 | 6 | 11 | 15 | 10 | 3 | 16 | 18 | 18 | 14 | 38 | 31 | 39 | |
69 | 67 | 69 | 74 | 83 | 86 | 43 | 84 | 116 | 117 | 136 | 139 | 100 | |
Total Liabilities | 107 | 107 | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 275 |
4 | 4 | 6 | 8 | 12 | 12 | 12 | 12 | 14 | 14 | 14 | 13 | 13 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
99 | 102 | 109 | 117 | 130 | 157 | 133 | 181 | 218 | 230 | 277 | 289 | 260 | |
Total Assets | 107 | 107 | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 275 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | -0 | 3 | 6 | 1 | -20 | 1 | 3 | 5 | 0 | -1 | -3 | |
-3 | 2 | -2 | -3 | -5 | -1 | -1 | -1 | -3 | -3 | 0 | -2 | |
-1 | -1 | -2 | -2 | 4 | 23 | -2 | -2 | -2 | 2 | 1 | 6 | |
Net Cash Flow | -1 | 0 | -1 | 1 | -1 | 2 | -3 | 0 | 0 | -0 | 1 | 1 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 141 | 119 | 114 | 108 | 75 | 100 | 109 | 118 | 170 | 101 | 165 | 170 |
Inventory Days | 16 | 10 | 7 | 3 | 5 | 16 | 23 | 21 | 20 | 11 | 26 | 33 |
Days Payable | 146 | 119 | 117 | 108 | 71 | 84 | 40 | 98 | 120 | 86 | 115 | 123 |
Cash Conversion Cycle | 11 | 9 | 5 | 3 | 9 | 32 | 92 | 42 | 69 | 26 | 76 | 80 |
Working Capital Days | 64 | 62 | 68 | 61 | 44 | 72 | 94 | 121 | 110 | 76 | 118 | 132 |
ROCE % | 4% | 6% | 7% | 7% | 22% | 14% | 12% | 8% | 9% | 10% | 6% | 6% |
Documents
Announcements
-
EGM Notice
6 Dec - Notice for 5th Extraordinary General Meeting on 02nd January 2025.
-
Reg 30 Notice Of General Meeting
6 Dec - Notice for 5th Extraordinary General Meeting on 02nd January 2025.
-
Announcement under Regulation 30 (LODR)-Meeting Updates
4 Dec - Approval for issuance of 50 lakh warrants and director reappointments.
-
Announcement under Regulation 30 (LODR)-Change in Management
4 Dec - Approval for issuance of 50 lakh warrants and director reappointments.
-
Announcement under Regulation 30 (LODR)-Preferential Issue
4 Dec - Approval for issuance of 50 lakh warrants and director reappointments.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
ADPL does manufacturing of active pharmaceutical ingredients, intermediates, specialty chemicals, and trading of industrial solvents & chemicals. It caters to pharmaceuticals formulation manufacturers and pharmaceutical merchant exports.